lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p

References

• Luminari S. Bridging the gap between epidemiology and clinical research in lymphoma. Leuk Lymphoma. 2013;54(9):1855–1856.
   PubMed Web of Science ®Google Scholar
• Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011;21(5):293–298.
   PubMed Web of Science ®Google Scholar
• Offner F, Samoilova O, Osmanov E, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015;126(16):1893–1901.
   PubMed Web of Science ®Google Scholar
• Zhao H, Tang DZ, Zhu J, et al. Diffuse large B cell lymphoma presented as trigeminal neuralgia: 2 cases reported and literature review. World Neurosurg. 2019;123:383–389.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018;131(21):2307–2319.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117–4126.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12–23.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016;2016(1):366–378.
   PubMed Web of Science ®Google Scholar
• Spizzo R, Almeida MI, Colombatti A, et al. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31(43):4577–4587.
   PubMed Web of Science ®Google Scholar
• Dousti F, Shahrisa A, Ansari H, et al. Long non-coding RNAs expression levels in diffuse large B-cell lymphoma: an in silico analysis. Pathol Res Pract. 2018;214(9):1462–1466.
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–463.
   PubMed Web of Science ®Google Scholar
• Zhou M, Zhao H, Xu W, et al. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. Mol Cancer. 2017;16(1):16.
   PubMedGoogle Scholar
• Wang QM, Lian GY, Song Y, et al. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. Life Sci. 2019;231:116335.
   PubMed Web of Science ®Google Scholar
• Zhao CC, Jiao Y, Zhang YY, et al. Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt/β-catenin pathway by sponging miR-135b-5p to elevate expression of APC. Cell Death Dis. 2019;10(4):252.
   PubMed Web of Science ®Google Scholar
• Chen LY, Zhang XM, Han BQ, et al. Long noncoding RNA SNHG12 indicates the prognosis and accelerates tumorigenesis of diffuse large B-cell lymphoma through sponging microR-195. Onco Targets Ther. 2020;13:5563–5574.
   PubMed Web of Science ®Google Scholar
• Jiao P, Hou J, Yao M, et al. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer. Biomed Pharmacother. 2019;117:109164.
   PubMed Web of Science ®Google Scholar
• Zhang YY, Li M, Xu YD, et al. LncRNA SNHG14 promotes the development of cervical cancer and predicts poor prognosis. Eur Rev Med Pharmacol Sci. 2019;23(9):3664–3671.
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–469.
   PubMed Web of Science ®Google Scholar
• Feng Y, Xing Y, Liu Z, et al. Integrated analysis of microRNA and mRNA expression profiles in rats with selenium deficiency and identification of associated miRNA-mRNA network. Sci Rep. 2018;8(1):6601.
   PubMedGoogle Scholar
• Yanaihara N, Harris CC. MicroRNA involvement in human cancers. Clin Chem. 2013;59(12):1811–1812.
   PubMed Web of Science ®Google Scholar
• Ghazanchaei A, Mansoori B, Mohammadi A, et al. Restoration of miR-152 expression suppresses cell proliferation, survival, and migration through inhibition of AKT-ERK pathway in colorectal cancer. J Cell Physiol. 2018;234(1):769–776.
   PubMed Web of Science ®Google Scholar
• You W, Zhang X, Ji M, et al. MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells. Int J Biol Sci. 2018;14(6):644–653.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:S185–S198.
   PubMed Web of Science ®Google Scholar
• Laurent C, Charmpi K, Gravelle P, et al. Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology. 2015;4(8):e1026530.
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–452.
   PubMed Web of Science ®Google Scholar
• Payandeh Z, Khalili S, Somi MH, et al. PD-1/PD-L1-dependent immune response in colorectal cancer. J Cell Physiol. 2020;235(7-8):5461–5475.
   PubMed Web of Science ®Google Scholar
• Phung CD, Nguyen HT, Choi JY, et al. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death. J Control Release. 2019;315:126–138.
   PubMed Web of Science ®Google Scholar
• Xie F, Xu M, Lu J, et al. The role of exosomal PD-L1 in tumor progression and immunotherapy. Mol Cancer. 2019;18(1):146.
   PubMed Web of Science ®Google Scholar
• Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol. 2016;28(8):383–391.
   PubMed Web of Science ®Google Scholar
• Davis RJ, Van Waes C, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016;58:59–70.
   PubMed Web of Science ®Google Scholar
• Zha H, Han X, Zhu Y, et al. Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade. Oncoimmunology. 2017;6(10):e1349587.
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981.
   PubMed Web of Science ®Google Scholar
• Shi X, Cui Z, Liu X, et al. LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 2019;510(4):594–600.
   PubMed Web of Science ®Google Scholar
• Yan Y, Han J, Li Z, et al. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma. Mol Med Rep. 2016;13(6):5125–5131.
   PubMed Web of Science ®Google Scholar
• Liu Z, Yan Y, Cao S, et al. Long non-coding RNA SNHG14 contributes to gastric cancer development through targeting miR-145/SOX9 axis. J Cell Biochem. 2018;119(8):6905–6913.
   PubMed Web of Science ®Google Scholar
• Li J, Wang AS, Wang S, et al. LncSNHG14 promotes the development and progression of bladder cancer by targeting miRNA-150-5p. Eur Rev Med Pharmacol Sci. 2019;23(3):1022–1029.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang Y, Zhang W, et al. Long non-coding RNA SNHG14 exerts oncogenic functions in non-small cell lung cancer through acting as an miR-340 sponge. Biosci Rep. 2019;39(1):BSR20180941.
   PubMedGoogle Scholar
• Liu G, Ye Z, Zhao X, et al. SP1-induced up-regulation of lncRNA SNHG14 as a ceRNA promotes migration and invasion of clear cell renal cell carcinoma by regulating N-WASP. Am J Cancer Res. 2017;7(12):2515–2525.
   PubMed Web of Science ®Google Scholar
• Wang Q, Teng Y, Wang R, et al. The long non-coding RNA SNHG14 inhibits cell proliferation and invasion and promotes apoptosis by sponging miR-92a-3p in glioma. Oncotarget. 2018;9(15):12112–12124.
   PubMedGoogle Scholar
• Zhao X, Tian X. Knockdown of long noncoding RNA HOTAIR inhibits cell growth of human lymphoma cells by upregulation of miR-148b. J Cell Biochem. 2019;120(8):12348–12359.
   PubMed Web of Science ®Google Scholar
• Chen J, Lin Y, Jia Y, et al. LncRNA HAND2-AS1 exerts anti-oncogenic effects on ovarian cancer via restoration of BCL2L11 as a sponge of microRNA-340-5p. J Cell Physiol. 2019;234(12):23421–23436.
   PubMed Web of Science ®Google Scholar
• Sun J, Tian X, Zhang J, et al. Regulation of human glioma cell apoptosis and invasion by miR-152-3p through targeting DNMT1 and regulating NF2: MiR-152-3p regulate glioma cell apoptosis and invasion. J Exp Clin Cancer Res. 2017;36(1):100.
   PubMedGoogle Scholar
• Shi J, Zhang Y, Qin B, et al. Long non-coding RNA LINC00174 promotes glycolysis and tumor progression by regulating miR-152-3p/SLC2A1 axis in glioma. J Exp Clin Cancer Res. 2019;38(1):395.
   PubMed Web of Science ®Google Scholar
• Ramalho-Carvalho J, Gonçalves CS, Graça I, et al. A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97. Clin Epigenetics. 2018;10:40.
   PubMed Web of Science ®Google Scholar
• Yin T, Liu MM, Jin RT, et al. miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8. Pathol Res Pract. 2019;215(6):152406.
   PubMed Web of Science ®Google Scholar
• Marques JHM, Mota AL, Oliveira JG, et al. Melatonin restrains angiogenic factors in triple-negative breast cancer by targeting miR-152-3p: in vivo and in vitro studies. Life Sci. 2018;208:131–138.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang YW, Gao P. SPIN1, negatively regulated by miR-148/152, enhances adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer. J Exp Clin Cancer Res. 2018;37(1):100.
   PubMedGoogle Scholar
• Zheng JF, Guo NH, Zi FM, et al. Long noncoding RNA H19 promotes tumorigenesis of multiple myeloma by activating BRD4 signaling by targeting MicroRNA 152-3p. Mol Cell Biol. 2019;40(3):e00382–e00319.
   Web of Science ®Google Scholar